Parantu K. Shah - Concepedia

Author

Parantu K. Shah

Dana-Farber Cancer Institute ORCID

Also Known As

P K Shah, P. Shah, P.K. Shah, Parantu K Shah, Parantu K. Shah, Parantu Krushnakant Shah, Parantu Shah, Parantu K. Shah

Publications

7.8K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Harvard University Inserm University of Chicago

About

Parantu K. Shah is an author at Dana-Farber Cancer Institute specializing in medicine, cancer research, and functional genomics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	1.9K
2	Natural Sciences	3	3	351
3	Engineering	2	2	74
4	Public Health	1	1	14
5	Biology	1	1	52

Parantu K. Shah

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Identification of Functional Elements and Regulatory Circuits by <i>Drosophila</i> modENCODE Sushmita Roy, Jason Ernst, Peter V. Kharchenko, Science	2010	1.3K
A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance Dharminder Chauhan, Ze Tian, Benjamin Nicholson, Cancer Cell Hematological MalignancyMalignant Blood DisorderApoptosisImmunologyHematology	2012	575
A cis-regulatory map of the Drosophila genome Nicolas Nègre, Lijia Ma, Christopher A. Bristow, Nature Transcriptional RegulationGeneticsGenomic MechanismDrosophila GenomeGene Regulatory Network	2011	531
A Comprehensive Map of Insulator Elements for the Drosophila Genome Nicolas Nègre, Parantu K. Shah, Pouya Kheradpour, PLoS Genetics	2010	342
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies Bhavatarini Vangamudi, Thomas A. Paul, Parantu K. Shah, Cancer Research Atpase DomainExclusive Catalytic SubunitsDrug TargetMolecular BiologyCancer Biology	2015	266
Information extraction from full text scientific articles: Where are the keywords? Parantu K. Shah, Carolina Perez‐Iratxeta, Peer Bork, BMC Bioinformatics	2003	196
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial Sandra P. D’Angelo, Shailender Bhatia, Andrew S. Brohl, Journal for ImmunoTherapy of Cancer	2020	193
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression Sujun Hua, Caleb B. Kallen, Ruby Dhar, Molecular Systems Biology Histone ModificationsChromatinVariant H2a.zChromatin RemodelingEpigenetic Change	2008	180
In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer Alessandro Carugo, Giannicola Genovese, Sahil Seth, Cell Reports	2016	146
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier, Journal for ImmunoTherapy of Cancer	2021	137

Page 1